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Smoking-related
interstitial lung
disease
S. Cerri, P. Spagnolo, F. Luppi and L. Richeldi
Summary
Cigarette smoking has a clear epidemiological association with
lung diseases, characterised by chronic inflammation of both
the bronchiolar and the interstitial lung compartments. There
are several different smoking-related interstitial lung diseases,
mainly desquamative interstitial pneumonia, respiratory bron-
chiolitis-associated interstitial lung disease and pulmonary
Langerhans’ cell histiocytosis. The epidemiology of such diseases
is largely unknown, although the prevalence of cigarette smok-
ing, particularly in low-income developing countries, indicates
that smoking-induced interstitial lung disorders represent a high
burden of disease worldwide. The role of chest high-resolution
computed tomography has become increasingly important in
differential diagnosis and follow-up. A new entity, the syndrome
of combined pulmonary fibrosis and emphysema, emerged as
another important smoking-related lung disorder with a poor
prognosis, associated with the high prevalence of pulmonary
hypertension. At the moment the role of anti-inflammatory
and immunosuppressive treatment remains unclear, although
in clinical practice most of these patients will receive at least
one course of corticosteroid therapy. It is vital to stress the im-
portance of identifying these patients and helping them quit
smoking.
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Cigarettes kill about half of all lifetime users and as such, no other consumer product is asdangerous, or kills as many people. The number of total premature deaths related to tobacco
smoke worldwide exceeds 4 million each year. Tobacco kills more than AIDS, legal drugs, illegal
drugs, road accidents, murder and suicide combined [1]. At the same time, cigarettes are possibly
the most marketed product in the world. While there is no reliable estimate of global cigarette
marketing expenditures, it is clearly tens of billions of US dollars per year [1]. Smokers have a
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markedly increased risk of multiple cancers, particularly lung cancer, and are at far greater risk of
heart disease, strokes, lung emphysema and many other fatal and non-fatal diseases; among these,
interstitial lung disease (ILD) constitutes a clinically relevant group. The lungs and the airways are
the main target of over 4,000 chemicals carried by cigarette smoke; most of these molecules have
marked irritant properties and some 60 are known or suspected carcinogens. So, it is not
surprising that many lung disorders have been linked to cigarette smoking for a long time. Among
these, diseases affecting the pulmonary interstitium have probably been less studied than others
and have only recently received the well-deserved attention due to their important clinical impact.
The link between cigarette smoking and the development of ILD has been initially built around the
association of tobacco smoking and the presence of these lung disorders, initially limited mainly to
desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung
disease (RB-ILD) and pulmonary Langerhans’ cell histiocytosis (PLCH) [2]; another important
support to the aetiological link between smoking and ILD came from the observation of clinical
and radiological regression of lung involvement upon smoking cessation, in particular in RB-ILD
[3]. Cigarette smoking may cause subclinical parenchymal lung disease detectable by spirometry
and computed tomography (CT) imaging, even among a generally healthy cohort [4, 5]. In recent
years it has become apparent that chest high-resolution CT (HRCT) scanning efficiently identifies
patients affected by smoking-related ILD, being more sensitive than measurements of pulmonary
function and cardiopulmonary exercise test parameters and this holds true even for subjects with
asymptomatic ILD [6]. As a consequence of combined better knowledge and improved diagnostic
skills, smoking-related ILD makes up a clinically relevant and challenging group of respiratory
diseases worldwide. Nonetheless, knowledge in this field is constantly increasing and changing
and a newly recognised causative role of smoking in several entities recently emerged. Among
smoking-related diseases, physicians and radiologists will relatively often identify patients with
ILD, such as PLCH, RB-ILD, DIP, acute eosinophilic pneumonia (AEP), the syndrome of com-
bined pulmonary fibrosis and emphysema (CPFE), rheumatoid arthritis-associated interstitial
lung disease (RA-ILD) or idiopathic pulmonary fibrosis (IPF). In this chapter, we will describe the
main clinical and radiographic findings of these clinical entities.
Pulmonary Langerhans’ cell histiocytosis
PLCH, also known as pulmonary histiocytosis X, is a disease characterised by the polyclonal
accumulation of CD1a+ dendritic cells (called Langerhans’ cells) in the lung [7]. This clinical
entity is part of a group of systemic diseases in which involvement of other organs (such as bone,
pituitary gland, thyroid, skin, lymph nodes and liver) also occurs [8]. The term PLCH identifies a
disease that develops in adults, characterised by significant lung involvement with or without the
involvement of other organs [9].
PLCH affects almost exclusively adult individuals in their third or fourth decades, who are either
active or former smokers. Lung involvement can also be seen in Langerhans’ cell histiocytosis
affecting children, although this is uncommon and usually present in the context of a multisystem
disease involving primarily other organs; in this case, the disease is not associated with smoking
habit and its pathobiology is considered to be different from the adult smoking-related form [9].
Disease mechanisms are not fully understood. The association with smoking history in ,95% of
the adults diagnosed with PLCH clearly suggests an important pathogenetic role. Cigarette smoke
might activate macrophages and/or epithelial cells to produce cytokines (such as tumour necrosis
factor (TNF)-a, transforming growth factor-b and granulocyte-macrophage colony-stimulating
factor) that could promote either recruitment or activation of Langerhans’ cells in the sub-
epithelial regions of the airways and surrounding areas [7, 10, 11]. Specific components of
cigarette smoke, such as tobacco glycoprotein, could also be involved in the direct activation of
inflammatory cells in the peribronchiolar areas, thus promoting the development of the specific
lesions. In addition, activated Langerhans’ cells and macrophages may promote the secondary
recruitment of other inflammatory cells, such as T-cells and eosinophils [7]. The disease develops
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in the peribronchiolar regions and, as a result, the histological hallmark is represented by the
formation of loosely formed nodules of mixed inflammatory cells surrounding the small airways,
in a bronchiolocentric fashion (fig. 1a) [12]. Nodules are usually bilateral and symmetric, with
predominant involvement of the upper lobes and sparing of lung bases. Initially cellular nodules
evolve to fibrotic lesions with a characteristic stellate appearance and central scarring [13]. The
destruction of bronchiolar walls leads to bronchiolar dilatation and cyst formation. Langerhans’
cells can be identified on histology by immunohistochemical staining for CD1a (fig. 1b) and by
the identification of intracellular Birbeck granules (pentalaminar rod-shaped intracellular
structures) on electron microscopy. Eosinophilic infiltration is often present, particularly in the
early phase of the disease [12].
While approximately 25% of patients are asymptomatic at the time of presentation, the presenting
symptoms are nonspecific and include dry cough and dyspnoea [14]. Pleuritic chest pain can also
be present and pneumothorax (often recurrent) is the initial manifestation in ,15% of patients.
Patients with associated systemic
involvement can present with addi-
tional symptoms that are related to
the affected organ, particularly the
skin, bone or pituitary gland.
Lung function tests can show either
obstructive, restrictive or mixed
abnormalities, even though they
can be normal in the early stage.
Reduced diffusing capacity of the
lung for carbon monoxide (DL,CO)
is present in a large proportion of
patients [14]. Limitations in the
exercise capacity can occur even in
the presence of mild pulmonary
function abnormalities and corre-
late better with markers of pul-
monary vascular dysfunction, as
development of pulmonary hyper-
tension (PH) may occur during the
course of the disease [15].
In the presence of a proper clinical
and radiological context (when
the chest HRCT highlights the
presence of typical features), the
demonstration of an elevated per-
centage (o5%) of CD1a+ cells in
the bronchoalveolar lavage fluid
(BAL) is diagnostic, thus preclud-
ing the need for a lung biopsy to
confirm the diagnosis [7, 16].
In the treatment of PLCH, smok-
ing cessation is a crucial step, as it
leads to stabilisation of symptoms
in the majority of cases [14]. How-
ever, some patients might experi-
ence disease progression despite
smoking cessation. In patients
with progressive or severe diseases,
a)
b)
Figure 1. Pulmonary Langerhans’ cell histiocytosis. a)
Haematoxylin/eosin staining showing a stellariform peribronchiolar
nodule with expanded interstitial spaces, type 2 pneumocytes
hyperplasia and an inflammatory infiltrate comprising eosinophils
and histiocytes. b) Immunohistochemistry staining showing
Langerhans’ cells with reniform nuclei positive for CD1a (G. Rossi,
Section of Pathologic Anatomy, University Hospital Policlinic of
Modena, Modena, Italy; personal communication).
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a trial with corticosteroid treatment can be considered, although data on the therapeutic benefit
of corticosteroids are limited [17, 18]. Some case reports have shown a positive effect of the
chemotherapeutic agent cladribine (2-chlorodeoxyadenosine, 2-CdA) in the treatment of tumour-
like Langherans’ cell histiocytosis with lung involvement [19, 20], as well as in patients with PLCH
presenting with infiltrative disease and progressive deterioration of lung function [21]. In patients
who present with pneumothorax, pleurodesis should be performed because it reduces the risk of
recurrence and it is not a contra-indication for subsequent lung transplantation [22].
Prognosis is generally good with an,13-yr median survival from time of diagnosis and 74.6% and
63.9% survival at 5 and 10 yrs, respectively [14].
Respiratory bronchiolitis-associated interstitial lung disease
Respiratory bronchiolitis is a very common finding in cigarette smokers, and was described for
the first time in 1974 [23]. On histology, the typical abnormality is represented by a peribronchio-
lar accumulation of pigmented macrophages. Because these lesions can be observed in virtually
all smokers, respiratory bronchiolitis can be considered as a histological marker of smoking.
However, in 1987 [24] a new disease entity, now named RB-ILD [25], was described. The term was
used to identify a disease occurring in heavy smokers, who presented with a restrictive ventilatory
defect and radiological abnormalities indicative of interstitial lung disease, in which the only
histological finding was represented by respiratory bronchiolitis [24].
The disease occurs in relatively young adults aged between 30 and 60 yrs, without sex predilection
[26]. Virtually all patients are cigarette smokers, although a clinical syndrome indistinguishable
from RB-ILD has been rarely described in subjects exposed to other sources of fumes [27, 28]. On
histology, the disease is characterised by airway-centred accumulation of yellow-brown pigmented
macrophages within distal bronchioles, alveolar ducts and adjacent alveolar spaces (fig. 2) [13].
Mild chronic interstitial inflammation and/or fibrosis of the peribronchiolar alveolar septa can be
present, but honeycombing is uncommon [27–29]. However, there are no histological features
that can distinguish RB-ILD from respiratory bronchiolitis and the definite diagnosis has to rely on a
combination of clinical and radiological findings, such as symptoms, pulmonary function abnor-
malities and imaging (particularly HRCT). Lung biopsy can provide a definitive diagnosis,
however, in the appropriate clini-
cal and radiological context, when
other causes of bronchiolar in-
flammation have been ruled out
(including infections or exposures),
there is no need for open lung
biopsy [28]. In contrast, while BAL
findings (increase in macrophage
numbers and lower percentages of
other cellular components) [30] are
not diagnostic for RB-ILD, the
differential cell count in BAL can
be very helpful in distinguishing
RB-ILD from other diseases pre-
senting with a similar appearance
on HRCT, particularly hypersensi-
tivity pneumonitis in which BAL
lymphocytosis is usually observed.
RB-ILD prognosis is generally
good and mortality is uncom-
mon. Smoking cessation is the key-
stone of RB-ILD management. For
Figure 2. Respiratory bronchiolitis-associated interstitial lung
disease. Haematoxylin/eosin staining showing a respiratory bronch-
iole with distorted architecture and accumulation of intra- and
peribronchial macrophages with golden cytoplasm (G. Rossi,
Section of Pathologic Anatomy, University Hospital Policlinic of
Modena, Modena, Italy; personal communication).
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patients with mild-to-moderate disease, smoking cessation can lead to significant and consistent
improvement of radiological abnormalities and lung function in a large proportion of cases [31, 32].
For patients with severe disease that does not improve following smoking cessation, a trial of
corticosteroid treatment with or without associated immunosuppressive drugs is usually undertaken
after a careful evaluation of risks and benefits of a prolonged treatment [24, 25, 28, 33], in fact,
evidence of effectiveness for corticosteroids and/or immunosuppressive drugs is not consistent
[31, 34]. Withdrawal of treatment in nonresponders is reasonable.
Desquamative interstitial pneumonia
DIP was first described by LIEBOW et al. [35] in 1965. In the original description, cells filling the
alveolar space were thought to be desquamated alveolar epithelial cells, so the disease was termed
desquamative. However, it was later recognised that cells are actually pigmented alveolar macrophages
accumulating in the alveolar spaces. Macrophages accumulating in DIP appear to be identical to
those seen in RB-ILD, although their distribution is different [36], in fact, RB-ILD is mainly
bronchiolocentric, while DIP is characterised by diffuse involvement of pulmonary acini. Some
authors would argue that RB-ILD and DIP can belong to the same clinical entity, therefore
representing a continuum in the spectrum of injury associated with cigarette smoke exposure [37].
However, while RB-ILD is almost invariably associated with cigarette smoking, incidence of smoking
in DIP is described in at least two-thirds of patients (60–90% in different case series), but cases of DIP
associated with other causes (such as autoimmune diseases, pneumoconioses or drug reactions) have
been described [38].
DIP generally presents in the fourth to sixth decade and symptoms are nonspecific, mostly characterised
by insidious progressive dyspnoea and non-productive cough [31]. Pulmonary function tests show a
restrictive ventilatory defect in one-third of patients and mixed defects in approximately the other two-
thirds of patients, however, lung function can be normal in up to 10–20% of patients [26].
On histology, DIP is characterised by accumulation of pigmented macrophages diffusely
distributed within alveolar spaces, and hyperplasia of type II pneumocytes (fig. 3) [39]. Variable
degrees of diffuse alveolar wall thickening can be associated with the disease, due to fibrosis and
mild infiltration of inflammatory cells. Alveolar wall architecture is preserved and honeycombing
is typically absent [39]. As mentioned previously, histological findings of RB-ILD and DIP largely
overlap, although a distinctive difference is in the distribution of the lesions, which are
bronchiolocentric in RB-ILD and much more diffuse in DIP [40]. Also, the extent of interstitial
fibrosis tends to be more prominent in DIP compared with RB-ILD [39].
A definite diagnosis of DIP can only be established on the basis of an open-lung surgical biopsy, as
clinical features, HRCT and BAL findings are nonspecific [36, 40].
In the management of DIP, smoking cessation is obviously mandatory. However, unlike RB-ILD,
patients with DIP can progress to respiratory failure, particularly those who continue smoking. In
a series of 23 cases of DIP, three deaths from respiratory failure due to progressive diffuse lung
disease have been reported [31]. Prolonged remission of DIP after smoking cessation has also been
described [18]. Due to a generally more severe impairment in lung function compared to RB-ILD,
early treatment with corticosteroids is usually undertaken, slowly tapered over a period of 3–
6 months. However, success of corticosteroid treatment is inconsistent [31]. Immunosuppressive
drugs, such as azathioprine and methotrexate, have been used in patients with DIP not responding
to corticosteroids [41]. Lung transplant remains an option in patients with progressive disease and
severe lung function impairment.
Acute eosinophilic pneumonia
AEP was firstly described in 1989 as an acute illness presenting with fever, hypoxaemia and
possible respiratory failure, diffuse pulmonary infiltrates and increased numbers of eosinophils in
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the BAL [42]. In many cases the
causative agent is unknown, al-
though a causal relationship with
potential respiratory exposure has
been highlighted, as patients have
reported a variety of activities
within days before the onset of
disease, such as cave exploration,
plant repotting, wood pile moving,
smoke-house cleaning, motocross
racing in dusty conditions, indoor
renovation work and tank cleaning
[43, 44]. Moreover, several cases
have been reported following to-
bacco smoking, particularly soon
after initiation of smoking or sig-
nificant increase in smoking habit,
with recurrence of symptoms after
repeat of exposure [45–47].
AEP usually occurs in young adults
(mean age of ,30 yrs), although
with a wide age range [43, 44, 48].
A male predominance has been
reported and the disease is not
associated with prior asthma his-
tory [49].
Pathogenesis is largely unknown,
existing evidence suggests that
acute exposure to cigarette smoke
can promote a T-helper cell type
2 inflammatory response which
would promote the recruitment of
eosinophils to the lung [50], which
in turn can then mediate lung
damage by the release of soluble
factors contained in the eosinophi-
lic granules [50].
The disease is characterised by an
acute onset, presenting symptoms are nonspecific and include cough, dyspnoea, fever and chest
pain. Severe hypoxaemia can be present, with many patients fulfilling the diagnostic criteria of
acute lung injury or acute respiratory distress syndrome requiring mechanical ventilation [43, 44].
In the proper clinical context, diagnosis can be made on the basis of differential cell count in BAL,
with eosinophils .20% [51]. By contrast, peripheral blood eosinophil count can be normal at
presentation, but generally rises to high values during the course of the disease. Transbronchial
biopsy will show aspects of acute and organising diffuse alveolar damage associated with
prominent interstitial and alveolar eosinophilic infiltration and interstitial oedema [52]. Although
spontaneous recovery may occur, a treatment with corticosteroids is usually prescribed and leads
to prompt resolution of symptoms and radiological abnormalities within weeks, without relapse
[51]. The majority of patients will not have long-term sequelae, however, some patients have
reported exertional dyspnoea with mild restrictive lung disease up to 1 yr later [52]. Smoking
cessation should be strongly advised in patients in whom the disease was possibly associated with
smoking exposure.
a)
b)
Figure 3. Desquamative interstitial pneumonia (DIP). a)
Haematoxylin/eosin staining showing a fibrotic process with homo-
geneous involvement of the lung characterised by dense fibrosis of
the interstitium and collection of macrophages into the alveoli. b)
High-power view of DIP histology showing accumulation of
pigmented macrophages within the alveoli (G. Rossi, Section of
Pathologic Anatomy, University Hospital Policlinic of Modena,
Modena, Italy; personal communication).
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Combined pulmonary fibrosis and emphysema
CPFE refers to the co-existence of upper lobe centrilobular, and frequently, paraseptal emphysema
(resulting from smoking) and lower lobe fibrosis (mainly of the usual interstitial pneumonia (UIP)
radiologic pattern), although emphysema and fibrosis may co-occur in the same area of the lung.
Physiologically, preserved lung volumes, markedly impaired diffusing capacity and hypoxaemia on
exercise characterise CPFE. This syndrome is also a strong determinant of secondary PH, which, in
turn, negatively affects survival [53]. The incidence of CPFE remains unknown, but it has been
reported to be as high as 35% amongst patients with IPF [54, 55]. In 1990 WIGGINS et al. [56]
described eight patients with coincidental pulmonary fibrosis and emphysema, but COTTIN et al. [53]
were the first to report on a homogeneous group of 61 patients, all but one male and all current or
ex-smokers. The median age at diagnosis, prevalence of digital clubbing (43%), presence of velcro-
type bibasal end-inspiratory crackles on chest auscultation and the BAL cellular profile were similar
to those observed in IPF. Spirometry and total lung capacity were normal in as many as 25% of the
patients; in this regard, hyperinflation of the emphysematous areas of the lungs are likely to
compensate the volume loss due to fibrosis of the lower lobes, while emphysema and fibrosis may
have additive or synergistic effects on reducing the DL,CO and determining exercise hypoxaemia. As a
consequence, CPFE may be under-recognised in patients with subnormal or normal spirometry if
DL,CO and/or exercise blood gases are not measured. Furthermore, lung volumes, which are usually
evaluated in the course of IPF, may not be relevant for the follow up of patients with CPFE. In this
scenario, changes in diffusion capacity, hypoxaemia, or pulmonary artery pressure, could represent
better surrogates for disease progression and mortality. The members of the French GERM‘‘O’’P
(Groupe d’Etude et de Recherche sur les Maladies ‘‘Orphelines’’ Pulmonaires) reported the
prevalence of PH to be 47% at diagnosis, although echocardiography was performed only in patients
with advanced disease; thus, the study population might have been skewed towards a more severe
disease phenotype, which may not represent the totality of patients with CPFE. However, NATHAN
et al. [57] found a similar prevalence of PH (40%) amongst 118 IPF patients who underwent right
heart catheterisation.
MEJIA et al. [55] reported that severe PH, as assessed by echocardiography (estimated systolic
pulmonary artery pressure (Ppa) .75 mmHg) was present in 21 out of 29 patients with CPFE
compared with eight out of 68 patients with IPF without emphysema (p,0.0001; odds ratio 19).
Furthermore, 19 out of 68 ‘‘typical’’ IPF patients displayed normal values of estimated systolic Ppa,
as compared with none of the IPF patients with concomitant emphysema. CPFE was also
associated with shorter survival (p50.01), an outcome determined by severe PH and not only by
the presence of the associated emphysema [55]. Of note, in this series not only a restrictive pattern
of disease was common (mean forced vital capacity (FVC) of 62% predicted) but a FVC ,50%
pred was also the most important variable associated with mortality, together with estimated
systolic Ppa .75 mmHg, raising the suspicion that patients with more advanced fibrosis than
emphysema may have been selected, thus hampering the generalisation of these results to the
entire population of patients with CPFE. In fact, a recent report from the USA confirms that CPFE
patients who are current or former cigarette smokers, have significantly larger lung volumes, have
more expiratory air flow obstruction and worse gas exchange, compared with patients with
isolated pulmonary fibrosis. However, in this study CPFE patients did not exhibit higher mortality
[58]. COTTIN et al. [59] described the haemodynamic and survival characteristics of 40 patients
with CPFE and PH confirmed by right heart catheterisation. Although no formal comparison
could be made from this retrospective study, the authors observed that patients with PH and CPFE
had a dismal prognosis, with a 60% probability of survival at 1 yr from the diagnosis of PH, which
is similar to the probability of survival at 1 yr in patients with IPF and associated pulmonary
hypertension at right heart catheterisation [55, 60], and worse than that of patients with chronic
obstructive pulmonary disease (COPD) and associated PH [61]. Interestingly, CPFE has also been
described in patients with ILD related to a concomitant connective tissue disease (CTD) [62],
patients with CPFE in the context of CTD appear to be younger and more frequently female, as
compared to a historical control group of patients with idiopathic CPFE.
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The putative mechanisms implicated in the combination of both types of lung destruction
(emphysema and fibrosis) are still largely unknown. While CPFE occurs only in smokers, many
smoker patients with IPF do not develop this pathological entity. In addition, it is unclear whether
emphysematous and fibrotic lesions progress independently or whether the development of one
affects the progression of the other. Experimental models reveal that over-expression of TNF-a in
mouse lungs provokes dramatic changes in both lung structure (airspace dilatation, consolidation
and fibrosis) and function [63]. However, no differences in TNF-a expression by macrophages or
bronchiolar epithelial cells have been found between IPF with and without emphysema in humans
[64]. Whether the association of lung fibrosis and emphysema represents a separate clinical entity
or simply a different clinical phenotype remains a matter of an intense debate. More robust
evidence that the syndrome has either prognostic or management significance is now needed:
specifically, it remains unclear whether the presence of emphysema has a separate effect on
survival, once baseline lung function severity is taken into account [54].
Rheumatoid arthritis-associated ILD
Rheumatoid arthritis (RA) is quite a common systemic inflammatory disease that affects ,1% of
the general population [65]. In RA, lung involvement is not infrequent and it can consist of
various manifestations including pleuritis and pleural effusion, rheumatoid nodules, bronch-
iectasis and ILD [66]. ILD is certainly one of the most common manifestations of lung
involvement in RA and various patterns of disease have been described [67]. In the context of
CTD, terminology to describe associated ILD has been basically derived from what is used to
define idiopathic interstitial pneumonias (IIPs), in fact, the same histopathological and radio-
logical patterns that identifies IIPs, can be found in association with CTD, and a high level of
suspicion is required to distinguish between idiopathic and non-idiopathic diseases. While in the
majority of CTD-associated ILD the nonspecific interstitial pneumonia (NSIP) pattern is most
often recognised, in RA-ILD the pattern of UIP is found to be the most common (56%), followed
by NSIP (33%) and organising pneumonia (OP) (11%) [67]. Among these patterns, a diagnostic
dilemma could be raised in distinguishing between UIP and NSIP patterns, particularly when a
confident diagnosis of UIP pattern cannot be made on the basis of HRCT findings. However,
while the importance of the distinction between UIP and NSIP is certainly well recognised in the
idiopathic diseases (in which there is a prognostic correlate because survival is better in NSIP
compared with UIP), whether this distinction has a clinical relevance in CTD-ILD is still an open
question for the most part. In the context of RA-ILD, data available so far would suggest that
patients presenting with UIP pattern have a worse prognosis (with higher risk of disease
progression and acute worsening of the disease) compared with those presenting with NSIP
pattern [68–70]. Moreover, patients with RA-ILD with UIP pattern seem to be less likely to
respond to corticosteroid and immunosuppressive therapies [71].
In RA, articular disease generally precedes any sign of lung involvement, however, some patients
may present with isolated pulmonary disease in the first place. Extra-articular disease (particular
lung involvement) can be a significant cause of morbidity and mortality in RA patients [67]. The
incidence of RA-ILD varies in different reports partly because of the detection methods that have
been used. Also, although a fairly large proportion of patients with RA might have HRCT
abnormalities consistent with ILD [72], clinically significant disease is present in a fewer number
of cases, thus, according to the latest estimates, clinically significant RA-ILD occurs in nearly 10%
of patients [73, 74]. A recently published paper by OLSON et al. [74] reports the analyses of
mortality data for RA and RA-ILD in a large study in the USA, which assessed all death certificates
from 1998 to 2004. This study showed that, while overall mortality rates for RA declined over time
(probably due to the effect of therapies), this was not the case for RA-ILD-associated mortality,
particularly in the older age groups. In addition, mean age at death was significantly lower in RA-
ILD patients compared with those without associated ILD and patients with RA-ILD were more
likely to die of RA complications or pulmonary diseases than of other comorbidities.
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Pathogenesis of RA-ILD is still not completely understood and it probably depends on both genetic
and environmental factors. A higher frequency of human leukocyte antigen (HLA) B40 and lower
frequency of HLA-DR4 have been reported in patients with RA and pulmonary fibrosis [75, 76]. In
addition, one study showed evidence of a1-antitrypsin deficiency in patients with RA and associated
pulmonary disease [77]. Although RA is more common in females, there has been a higher frequency
of RA-ILD in males with long-standing disease reported, and it has been thought that this might
reflect a greater frequency of smoking in males compared with females. A relationship between
smoking and RA leads to the observation that smoking is implicated in the increased risk of RA and
disease severity [78, 79]. However, smoking is also the greatest environmental risk factor for lung
diseases, including ILDs. Further support for the potential role of smoking in RA-ILD derives from
a large study on 336 patients with RA, in which not only the severity of RA was shown to be an
independent predictor of ILD, but also a significant smoking history (.25 pack-yrs) was associated
with radiographic evidence and lung function abnormalities suggestive of ILD [80]. Furthermore,
smoking habit seems to correlate with the type of pattern of lung involvement, as smokers tend to
present with predominant UIP-like abnormalities [81, 82].
Presenting symptoms of RA-ILD are usually progressive dyspnoea and chronic dry cough and lung
function generally shows a restrictive ventilatory pattern and a reduced DL,CO. HRCT abnormalities
will vary depending on the prevalent pattern of the disease, with the UIP pattern being the most
common in RA-ILD, followed by the NSIP pattern [67]. There is a good correlation between the
HRCT appearance and the histopathology pattern, particularly when radiologic findings are
consistent with UIP; therefore, lung biopsy is not always required for the diagnosis of RA-ILD and is
not routinely recommended, given the risks of a surgical lung biopsy in these patients [83].
While much progress has been made in the treatment of articular manifestations of RA, it does not
seem to be the case for the management of pulmonary manifestations of the disease. At present,
decisions on treatment for RA-ILD are still taken on an empiric basis [66]. Corticosteroids are often
used as a first-line therapy, but results seem to be inconsistent, while histology is lacking most of the
time, it appears that patients with RA associated with a NSIP pattern or OP are more likely to
respond to steroids compared with those with an associated UIP pattern [71]. Experience with
immunosuppressive drugs is limited: cyclophosphamide, cyclosporine, azathioprine, hydroxychlor-
oquine and mycophenolate mofetil can be considered in the management of patients not responding
to corticosteroids or as steroid-sparing agents in long-term maintenance treatment [66]. Whether
TNF-a inhibitors might be useful in the treatment of RA-ILD, as they certainly have proven to be in
the management of RA without lung disease, is still unclear. Some evidence seems to suggest that
infliximab can lead to stabilisation of RA-ILD [84]. However, despite the introduction of these
drugs, the overall mortality for RA-ILD has increased [74] and some studies have suggested that
anti-TNF therapy can be associated with worsening of parenchymal lung disease [85, 86]. Lung
transplantation is still an option in patients not responding to medical treatment [66].
Idiopathic pulmonary fibrosis
IPF is a chronic, progressive and lethal lung disease of unknown aetiology. The exact incidence and
prevalence of this disease is unknown, but it appears to be more common than previously
supposed, with prevalence ranging from 0.8 to 64.7 per 100,000 individuals and incidence ranging
from 0.4 to 7.1 per 100,000 persons in the USA [87]. In the UK, the incidence of IPF has increased
progressively and more than doubled between 1990 and 2003 [88]. Both the prevalence and the
incidence of IPF augment markedly with age, with prevalence exceeding 175 cases per 100,000
individuals who are .75 yrs of age. Age also influences mortality and the median survival time is
significantly shorter in older individuals compared with younger ones [89].
The course of the disease is variable, with many patients remaining stable or progressing slowly for
long periods of time while some others exhibit an accelerated progression or experience acute
exacerbations leading to respiratory failure and death [90–93]. Although there are no compelling
data demonstrating that cigarette smoking is the direct cause of IPF, the majority of patients with
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the disease are current or former smokers, suggesting that cigarette smoke might act together with
other predisposing factors in determining the risk of disease. On surgical lung biopsy, IPF patients
show a typical spatially heterogeneous pattern characterised by the presence of fibroblast foci
(fig. 4). Patients with IPF are usually aged between 50 and 70 yrs, with a male predominance. The
pathogenesis of IPF is largely unknown. For a long time the disease was considered the result of a
chronic inflammatory reaction of the lung, followed by fibroblast proliferation/activation and finally
by the exaggerated accumulation of extracellular matrix proteins. However, in 2001 a new paradigm
for pathogenesis considered the epithelium as the primary site of injury and the driving force for the
cascade of events that lead to lung fibrosis [94]. According to this hypothesis, alveolar epithelial cell
microinjuries/apoptosis provoke the migration, proliferation and the aberrant activation of the
neighbouring epithelial cells, which in turn secrete the mediators responsible for the expansion of the
fibroblasts/myofibroblasts population in the IPF lungs. Source of fibroblasts/myofibroblasts in this
disease might be various. Traditional thinking believed that these cells derived from proliferation of
the resident pool of fibroblasts within the lung. However, two additional hypotheses have gained
evidence in recent years. First of all, alveolar epithelial cells may contribute to the increase of lung
fibroblasts/myofibroblasts through
a phenomenon named epithelial
to mesenchymal transition. Several
studies have revealed the presence
of lung cells showing epithelial and
mesenchymal markers in IPF, tran-
siting from alveolar epithelial
cells to myofibroblasts [95, 96].
However, fibroblasts may expand
through the recruitment into the
lung of a particular type of circu-
lating cells called fibrocytes. Fibro-
cytes are bone marrow-derived
cells that share both leukocyte
and mesenchymal markers (such
as CD45 and collagen I, respec-
tively) and there is growing evi-
dence supporting their role in IPF
pathogenesis and possibly as a
prognostic biomarker of disease
progression [97, 98]. This change
of perspective in IPF pathogenesis
in recent years has led to a different
approach to IPF treatment from
an anti-inflammatory/immunosup-
pressive profile to new drugs with
anti-fibrotic and perhaps anti-pro-
liferative action.
HRCT findings in
smoking-related ILDs
As with other diffuse parenchymal
lung diseases, chest HRCT is more
sensitive than chest radiography
and, in the correct clinical setting,
often suggests the diagnosis. Never-
theless, overlapping CT features
a)
b)
Figure 4. Idiopathic pulmonary fibrosis. a) Haematoxylin/eosin
staining showing the typical chronic fibrotic process characterised by
geographic/spatial and temporal heterogeneity with fibroblastic foci
of active fibrosis abruptly alternating with old fibrosis and honey-
combing changes. b) A fibroblastic focus at higher magnification
(6400) (G. Rossi, Section of Pathologic Anatomy, University Hospital
Policlinic of Modena, Modena, Italy; personal communication).
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observed across the spectrum of smoking-related ILDs may confound radiologic classification into
distinct entities and limit the histo-specificity of diagnoses made on HRCT.
HRCT features of RB-ILD include hazy centrilobular nodules predominating in the upper lobes and
small patches of ground-glass attenuation. Centrilobular nodules and ground-glass attenuation
appear to be accounted for by macrophage accumulation within respiratory bronchioles and in the
alveoli and alveolar ducts, respectively [99]. In RB-ILD these abnormalities are generally widespread
and often associated with a background of emphysema and bronchial wall thickening. Thickened
interlobular septa due to interstitial fibrosis may be seen in RB-ILD, but they rarely represent a
prominent feature. RB-ILD differs from DIP in that ground-glass attenuation of RB-ILD is usually
less extensive, patchier, and more poorly defined. Conversely, peripheral subpleural and basal
predominance of ground-glass opacity, reflecting either accumulation of intra-alveolar macrophages
or septal thickening, is most commonly seen in DIP [37]. Small cystic spaces, which differ from those
clustered of honeycombing, may develop within the areas of ground-glass opacity, and their
presence increases the diagnostic confidence for DIP [100]. Honeycombing, traction bronchiectasis
and architectural distortion of lung parenchyma are uncommon features of DIP. HRCT findings
typical of RB-ILD effectively exclude most other diffuse lung diseases, particularly the predominantly
fibrotic IIPs [36]. The combination of HRCT features of infiltrative and small airways disease is
similar to that seen in subacute hypersensitivity pneumonitis and the distinction between these two
conditions often rests on the smoking history because hypersensitivity pneumonitis is uncommon in
smokers. However, DIP may be radiologically indistinguishable from NSIP and some cases of UIP
with atypical HRCT appearance. Although HRCT may discriminate between DIP and RB-ILD the
overlapping features in some cases and the occasional histological co-existence of the two entities
complicates securing the correct diagnosis [37].
The HRCT features of PLCH closely mirror the macroscopic pathologic findings and depend on disease
stage. The nodules, which correspond to the early small airway-centred nodular infiltrate observed
histologically, are usually,5 mm in
diameter, have a peribronchiolar
and centrilobular distribution and
may cavitate. The extent of nodular
lesions correlates with the density of
granulomatous lesions in the bioptic
specimens [101]. In more advanced
stages, the cystic-nodular pattern
involving mostly the upper lobes
and frequently sparing the costo-
phrenic sulci, is virtually diagnostic
of PLCH. Cysts are usually
,10 mm in diameter but may
coalesce becoming .20 mm and
leading to bizarre-shaped spaces
with a bilobed, clover-leaf, or
branching appearance [102].
Nodules and cysts can occur inde-
pendently of each other, but in the
majority of patients they are found
concomitantly. Occasionally, patchy
or diffuse ground-glass opacity may
be seen, probably related to areas of
respiratory bronchiolitis and DIP
[40]. While in typical cases HRCT
appearance usually permits a con-
fident diagnosis, end-stage PLCH
may be difficult to distinguish from
Figure 5. Idiopathic pulmonary fibrosis (IPF). Typical chest high-
resolution computed tomography pattern of IPF characterised by
subpleural peripheral honeycombing in the lower lobes, traction
bronchiectasis and thickened interlobular septae.
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other cystic lung diseases, such as lymphangioleiomyomatosis, lymphocytic interstitial pneumonia and
emphysema, owing to a less obvious disease distribution [103].
The typical appearance of IPF on HRCT consists of patchy, predominantly peripheral, subpleural and
bibasilar reticular opacification (fig. 5). Areas of ground-glass attenuation may also be seen but rarely
represent the predominant feature.
Regions of dense reticulation, which
demonstrate involvement of me-
dium-sized airways and are known
as "traction bronchiectasis", are ob-
served in more advanced disease. The
presence of subpleural honeycomb-
ing, traction bronchiectasis and thick-
ened interlobular septae constitute a
highly specific radiographic pattern,
termed "confident" IPF, which, in the
right clinical setting, obviates the
need for lung biopsy [104, 105],
while less specific reticular patterns
seen on HRCT and termed ‘‘possi-
ble’’ IPF requires surgical lung biopsy
to confirm the diagnosis. However,
predominant ground-glass opacities,
nodular infiltrates, significant lym-
phadenopathy, or a predominance of
upper lobe infiltrates suggest alter-
native diagnoses. Recently, COTTIN
et al. [53] described a syndrome in
which IPF coexists with pulmonary
emphysema (CPFE). This is not
surprising since both diseases are
associated with a history of cigarette
smoke. CPFE, the incidence of which
has been suggested to be as high as
35% of IPF patients [54], is char-
acterised by upper lobe emphysema
(fig. 6a) and lower lobe fibrosis
(fig. 6b).
A reticular pattern with honey-
combing, and traction bronchiecta-
sis (with architectural distortion in
more severe cases) is the major
abnormality in advanced disease,
with ground-glass opacities being
the most common findings in
patients with early-onset RA [70].
TANAKA et al. [106] identified four
predominant HRCT patterns of
interstitial disease, UIP, NSIP, OP
and bronchiolitis, which have
proved to be excellent predictors of
the underlying pathology but are
indistinguishable from IIP [69, 106].
In addition, similar to idiopathic
a)
b)
Figure 6. Combined pulmonary fibrosis and emphysema (CPFE).
High-resolution computed tomography scan in a case of CPFE
showing a) predominant upper lobe emphysematous changes and
b) lower lobe dense fibrosis in the same patient.
2
9
3
S
.
C
E
R
R
I
E
T
A
L
.
diseases, radiographic patterns
appear to predict progression and
outcome in RA-ILD [104]. HRCT
is also important in the evaluation
of airway involvement, which is
common in RA. In unselected
patients bronchiectasis was seen in
20–30% on HRCT [107]. The
presence of centrilobular nodules,
hyperinflation, and a mosaic pat-
tern of air trapping on HRCT are
highly suggestive, and their co-
existence in interstitial pneumonia
suggests a diagnosis of RA-ILD
rather than IIP [108].
In patients with AEP, ground-glass
opacities and bilateral air space
consolidation are the most com-
mon patterns of parenchymal
lesions on chest CT imaging
(fig. 7). Poorly defined nodules
and interlobular septal thickening
are seen in a majority of patients,
with pleural effusion, usually bilat-
eral, being observed in at least
two-thirds of patients [109, 110].
Diagnostic approach to smoking-related ILD
Clinical suspicion of a smoking-related ILD should be raised in any smoker (or ex-smoker)
presenting with signs of chronic respiratory failure, e.g. digital clubbing and shortness of breath.
Obviously, the clinical findings among the different smoking-related ILDs are nonspecific (often
overlapping with the presentation of COPD) and even pulmonary function testing might be of
little help in differentiating the different forms of ILD. Onset of clinical manifestations is usually
insidious and gradual, with dyspnoea being the most prominent and disabling symptom. Patients
commonly also complain of mild nonspecific cough, which is often attributed to smoking, thus
resulting in typical delays of diagnosis. While cough is usually dry, it may also be productive of
mucoid sputum, especially in advanced disease. For the majority of patients with RB-ILD, DIP,
PLCH and AEP the onset of symptoms is usually in the fourth or fifth decades of life, considerably
earlier than in patients with IPF. While an acute presentation is uncommon in IPF, DIP, RB-ILD
and RA-ILD, AEP is a severe acute febrile illness with patients usually very dyspnoeic and
hypoxaemic. Constitutional symptoms, such as weight loss, low-grade fever, fatigue, chest pain
and haemoptysis may be reported in PLCH and RA-ILD, but are, otherwise, uncommon. Chest
auscultation may reveal inspiratory crackles predominantly located in the lower posterior lung
zones in the majority of cases. Digital clubbing is present in up to two-thirds of patients with IPF,
in roughly half of those with DIP [31, 111], and only occasionally in RB-ILD [112]. In PLCH
physical examination is frequently normal and auscultation of the lungs only occasionally reveals
scattered crackles or wheezes, whereas in the advanced stages of the disease decreased breath sounds
may be appreciated [113]. Furthermore, a minority of patients with PLCH may present with
spontaneous pneumothorax, which can be bilateral or recurrent, while ,25% of patients are
asymptomatic, with the disease being uncovered on a routine chest radiograph [114]. Pulmonary
function test results may show a mixed obstructive-restrictive pattern with reduced diffusing capacity in
RB-ILD, a marked reduction in diffusing capacity or restrictive defects in DIP, mild obstructive,
Figure 7. Acute eosinophilic pneumonia (AEP). High-resolution
computed tomography scan showing bilateral ground-glass opa-
cities and air space consolidation in a patient with AEP.
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restrictive, or mixed abnormalities with a reduction in diffusion capacity in PLCH, a restrictive defect
with reduced lung volumes and diffusing capacity in IPF and relatively preserved lung volumes despite
markedly impaired diffusing capacity and hypoxaemia during exercise in CPFE. Regardless of the
specific entity, patients with advanced disease may have hypoxaemia at rest or with exertion. A
summary of the main clinical and radiological features of smoking-related ILD is presented in table 1.
When combining all the clinical and radiological features, each of the smoking-related ILDs can be
uniquely identified as the result of a combination of clinical presentations, typical HRCT abnormalities
and, in some cases, characteristic laboratory findings (e.g. BAL differential cell count). However, in
clinical practice the differential diagnosis between RB-ILD and DIP could still represent a challenge.
HRCT findings typical of RB-ILD effectively exclude most of the other diffuse lung diseases, including
the predominantly fibrotic idiopathic interstitial pneumonias (mainly IPF and fibrotic NSIP). There is
occasional overlap in radiologic appearances between RB-ILD and DIP, although the ground-glass
attenuation of DIP is usually more extensive and nodules are infrequent or absent [29, 115]. HRCT
appearances of RB-ILD frequently resemble those of subacute hypersensitivity pneumonitis; in both
diseases, widespread poorly formed nodular abnormalities and areas of hypoattenuation may co-exist
[33, 116]. However, the combination of clinical history (RB-ILD occurs only in smokers, whereas
smokers are underrepresented among patients with hypersensitivity pneumonitis) and BAL profile
usually distinguishes between these two disorders [36]. In RB-ILD (and respiratory bronchiolitis alike),
a characteristic brown pigmentation of alveolar macrophages has been consistently observed [36].
Moreover, BAL findings in RB-ILD differ strikingly from those of hypersensitivity pneumonitis, in
which a BAL lymphocytosis is expected [117]. Therefore, BAL findings, in conjunction with clinical
history and chest HRCT findings, usually allow the diagnosis of RB-ILD to be made without the need
for thoracoscopic lung biopsy. By contrast, a thoracoscopic biopsy is almost invariably required to
diagnose DIP, as the chest HRCT appearance of extensive ground-glass attenuation and the increased
numbers of cells in BAL [30] are both nonspecific findings.
Conclusion
The fact that almost all cases of DIP, RB-ILD and PLCH occur in smokers clearly points to a direct
causal role of cigarette smoking in the pathogenesis of these disorders, furthermore, a crucial role
for cigarette smoking is apparent in AEP, IPF and CPFE. Currently, little is known on the
pathogenic mechanisms in these disorders, although it is becoming apparent that a combination
of environmental and genetic factors contributes to induction and maintenance of progressive
lung damage. These non-neoplastic entities represent an important group of diseases that any
chest physician will see, particularly in relatively young individuals, in the context of daily clinical
practice. As such, a timely identification and an appropriate treatment, usually based on corti-
costeroid therapy, are of crucial relevance for these patients. Finally, an obvious consequence is the
high-ranking in every physician’s clinical practice of knowledge and application of state-of-the-art
pharmacologic and non-pharmacologic interventions aimed at smoking cessation.
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